AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B
SAN FRANCISCO, May 28, 2025 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today…